Nanocarriers-based therapeutic strategy for drug-resistant epilepsy: A systematic review.

Autor: Diaz-Peregrino R; Department of Neurosurgery, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Electronic address: roberto.diaz_peregrino@stud.uni-heidelberg.de., San-Juan D; Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico., Patiño-Ramirez C; Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico., Sandoval-Luna LV; Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico., Arritola-Uriarte A; Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Jazyk: angličtina
Zdroj: International journal of pharmaceutics [Int J Pharm] 2025 Jan 05; Vol. 668, pp. 124986. Date of Electronic Publication: 2024 Nov 22.
DOI: 10.1016/j.ijpharm.2024.124986
Abstrakt: Background: Nanocarriers have been proposed as a solution for drug-resistant epilepsy.
Methods: A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus from March 2023 to March 2024.
Results: Eighteen studies were identified: 2 in vitro, 9 in vivo, and 7 combined. While epilepsy models and seizure control assessments were consistent, there was variability in evaluating the potential toxicity of nanocarriers. Only one study did not show a reduction in brain inflammation, seizures, and cell loss. Nanocarrier toxicity was evaluated just in six studies, all of which indicated low toxicity both in vitro and in vivo.
Conclusions: Nanocarriers with antiseizure drugs manage seizures, inflammation, oxidative stress, and behavior impairment in drug-resistant epilepsy. Furthermore, nanocarriers are a safe option for delivering antiseizure drugs, though more research is needed to confirm these findings.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: